AACI |
Association of American Cancer Institutes |
ACOSOG |
American College of Surgeons Oncology Group |
ACRIN |
American College of Radiology Imaging Network |
ALL |
acute lymphoblastic leukemia |
AMA |
American Medical Association |
AML |
acute myeloid leukemia |
ASCO |
American Society of Clinical Oncology |
ASO |
administrative services only |
BIQSFP |
Biomarker, Imaging, and Quality of Life Studies Funding Program |
BUN |
blood urea nitrogen concentration |
caBIG |
Cancer Biomedical Informatics Grid |
CALGB |
Cancer and Leukemia Group B |
CAM |
complementary and alternative medicine |
CBER |
Center for Biologics Evaluation and Research |
CCOP |
Community Clinical Oncology Program |
CCSG |
Cancer Center Support Grant |
CDER |
Center for Drug Evaluation and Research |
CDRH |
Center for Devices and Radiological Health |
CEBP |
CCAAT/Enhancer Binding Protein |
CED |
coverage with evidence development |
CIRB |
Central Institutional Review Board |
CLIA |
Clinical Laboratory Improvement Amendments |
CME |
continuing medical education |
CMS |
Centers for Medicare and Medicaid Services |
COG |
Children’s Oncology Group |
CPC |
Cancer Prevention and Control |
CPT |
Common Procedural Terminology |
CRADA |
Cooperative Research and Development Agreement |
CRF |
case report form |
CT |
computed tomography |
CTAC |
Clinical and Translational Research Advisory Committee |
CTEP |
Cancer Therapy Evaluation Program |
CTSU |
Cancer Trials Support Unit |
CTWG |
Clinical Trials Working Group |
DCTD |
Division of Cancer Treatment and Diagnosis |
ECOG |
Eastern Cooperative Oncology Group |
EMA |
European Medicines Agency |
ERISA |
Employee Retirement Income Security Act |
FDA |
Food and Drug Administration |
FLT3/ITD |
fms-like tyrosine kinase receptor-3/internal tandem duplication |
FOA |
Funding Opportunity Announcement |
GOG |
Gynecological Oncology Group |
HCPCS |
Healthcare Common Procedure Coding System |
HER2 |
human epidermal growth factor receptor 2 |
HHS |
U.S. Department of Health and Human Services |
IDE |
investigational device exemption |
IND |
investigational new drug |
IOM |
Institute of Medicine |
IP |
intellectual property |
IRB |
Institutional Review Board |
IT |
information technology |
KRAS |
Kirsten ras oncogene |
MTA |
Material Transfer Agreement |
NCCN |
National Cooperative Cancer Network |
NCCTG |
North Central Cancer Treatment Group |
NCI |
National Cancer Institute |
NDA |
new drug applications |
NHBLI |
National Heart, Lung, and Blood Institute |
NIH |
National Institutes of Health |
NLM |
National Library of Medicine |
NSABP |
National Surgical Adjuvant Breast and Bowel Project |
OEWG |
Operational Efficiency Working Group |
OHRP |
Office for Human Research Protections |
OPEN |
Oncology Patient Enrollment Network |
OSU |
Ohio State University |
PET-CT |
positron emission tomography-computed tomography |
PhRMA |
Pharmaceutical Research and Manufacturers of America |
PI |
principal investigator |
RECIST |
Response Evaluation Criteria in Solid Tumors |
RFA |
Request for Applications |
RTOG |
Radiation Therapy Oncology Group |
RUC |
Relative Value Scale Update Committee |
SACHRP |
Secretary’s Advisory Committee on Human Research Protections |
SJO |
St. Joseph Hospital, Orange, California |
sNDA |
supplemental new drug application |
SPA |
Special Protocol Assessment |
SPORE |
Specialized Program of Research Excellence |
START |
Standard Terms of Agreement for Research Trials |
SWOG |
Southwest Oncology Group |
TAILORx |
Trial Assigning IndividuaLized Options for Treatment |
TARGET |
Therapeutically Applicable Research to Generate Effective Treatments |